180 Life Sciences Corp.
ATNF
$-0.08
Change (1 day)
$17.75
Year High
$1.16
Year Low
Categories
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
180 Life Sciences Corp. (ATNF) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -921,739 | 5.39 M | 5.26 M | 3.64 M | |
| 2022 | -5,630,405 | 8.31 M | 19.65 M | 8.93 M | |
| 2021 | -6,266,987 | 23.39 M | 62.71 M | 11.2 M | |
| 2020 | 1.67 M | 25.25 M | 55.53 M | 4.01 M | |
| 2019 | 3.44 M | 13.31 M | 51.88 M | 748.29 K |